Elraglusib (9-ING-41): A Comprehensive Profile of a Clinically Promising Agent with a Contested Mechanism

Section 1: Executive Summary

Elraglusib (9-ING-41) is an investigational, first-in-class, small-molecule therapeutic developed by Actuate Therapeutics, Inc..[1] Originally conceived and advanced into clinical trials as a potent inhibitor of Glycogen Synthase Kinase-3 Beta (GSK-3β), a key enzyme implicated in numerous oncogenic signaling pathways, Elraglusib has demonstrated a compelling clinical profile, particularly in cancers with high unmet medical needs.[2] The most significant clinical achievement to date is from the randomized, controlled Phase 2 Actuate-1801 trial, where the addition of Elraglusib to standard-of-care chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival for patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).[3] This pivotal result has positioned Elraglusib as a potential paradigm-shifting treatment in one of oncology's most challenging indications.